Related references
Note: Only part of the references are listed.Disposition and Metabolism of GSK2251052 in Humans: A Novel Boron-Containing Antibiotic
Gary D. Bowers et al.
DRUG METABOLISM AND DISPOSITION (2013)
Challenges and opportunities in developing novel drugs for TB
Takushi Kaneko et al.
FUTURE MEDICINAL CHEMISTRY (2011)
Therapeutic potential of boron-containing compounds
Stephen J. Baker et al.
FUTURE MEDICINAL CHEMISTRY (2009)
Synthesis, Characterization, and Antifungal Activity of Boron-Containing Thiosemicarbazones
Justin W. Hicks et al.
CHEMISTRY & BIODIVERSITY (2008)
Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California
Sonya C. Valentine et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Application of a receptor pruning methodology to the enoyl-ACP reductase from Escherichia coli (Fabl)
Kerly F. M. Pasqualoto et al.
QSAR & COMBINATORIAL SCIENCE (2006)
The structural basis for hydrolysis resistance in the esters of (2-formylphenyl)boronic acid 2,4-dinitrophenylhydrazones
MP Groziak et al.
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS (2002)
A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase
CW Levy et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
Bacterial fatty acid biosynthesis: Targets for antibacterial drug discovery
JW Campbell et al.
ANNUAL REVIEW OF MICROBIOLOGY (2001)
Share Paper
